Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus
- 8 December 2008
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 126 (12), 1707-1715
- https://doi.org/10.1001/archopht.126.12.1707
Abstract
The Diabetes Control and Complications Trial (DCCT) was designed to determine whether intensive therapy with the aim of maintaining glycemic levels as close to the nondiabetic range as possible would prevent or delay the long-term complications of type 1 diabetes mellitus.1The DCCT demonstrated substantial reductions in the risk of development and progression of the early microvascular complications of diabetes over an average of 6.5 years of intensive therapy as compared with conventional therapy. At the close of the DCCT in 1993, patients in the conventional therapy group were offered intensive therapy and instructed in its use. All patients subsequently returned to their health care providers for further diabetes care and 97% of the original DCCT cohort (n = 1394) was enrolled in the Epidemiology of Diabetes Interventions and Complications (EDIC), a long-term observational study.2An earlier report showed that the ongoing risk of all levels of retinopathy remained significantly reduced in the intensive compared with the conventional group during the first 4 years of EDIC, despite similar glycated hemoglobin (HbA1c) levels over this period (called “metabolic memory”).3Determining the duration of metabolic memory is important to quantify the long-term clinical effects of intensive diabetes therapy. The current report describes the continuing differences between the 2 original treatment groups in retinal complications 10 years after the close of the DCCT.Keywords
This publication has 20 references indexed in Scilit:
- Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial CompletionDiabetes Care, 2006
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesThe New England Journal of Medicine, 2005
- Hemoglobin A1c Measurements over Nearly Two Decades: Sustaining Comparable Values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications StudyClinical Chemistry, 2005
- Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive TherapyThe New England Journal of Medicine, 2000
- Early Worsening of Diabetic Retinopathy in the Diabetes Control and Complications TrialAmerican Journal of Ophthalmology, 1998
- Are there any glycemic thresholds for the serious microvascular diabetic complications?Journal of Diabetes and its Complications, 1995
- The Effect of Intensive Diabetes Treatment on the Progression of Diabetic Retinopathy in Insulin-Dependent Diabetes MellitusAmerican Journal of Ophthalmology, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993
- Progression of Incipient Diabetic Retinopathy During Good Glycemic ControlDiabetes, 1987
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.Psychological Bulletin, 1968